This article was originally published at https://www.drugpatentwatch.com/blog/tracking-20-years-compound-target-output-literature-patents/ This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and… The post Tracking 20 Years of Compound-to-Target Output from Literature and Patents appeared first on DrugPatentWatch. The post […]
Welcome to BlogNotions' Life Sciences Blog
The BlogNotions Life Sciences Blog delivers a diverse series of perspectives provided by thought leaders in the life sciences industries. Presented by NetLine, this forum delivers compelling updates on the latest technological advances, discussions of research and findings, best practices for advancing education, implications for the future of various life sciences fields, and much more. Here you can find helpful information, ask questions, and collaborate freely.
In continuation of my update on chloroquine A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective for Zika virus. The drug, called chloroquine, has a long history […]
Dr. Reddy’s Laboratories Ltd. through its wholly owned subsidiary Promius Pharma, LLC, announced its fifth consecutive, first-cycle NDA approval for the Proprietary Products Group, a substantial milestone within the pharmaceutical industry. Impoyz (clobetasol propionate) Cream, 0.025% is a high potency topical steroid approved for the treatment of moderate to severe plaque psoriasis in patients 18 […]
In continuation of my update on Osimertinib Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine. EGFR mutations occur […]
By Larry Ramer, DrugPatentWatch writer Artificial intelligence, or AI, has advanced significantly in recent years and could significantly lower pharma companies’ R&D costs by enabling precision medicine and greatly reducing… The post Can Artificial Intelligence Help Drug Development? appeared first on DrugPatentWatch. The post Can Artificial Intelligence Help Drug Development? appeared first on Biotechblog.
In continuation of my update on soy milk Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists […]
This article was originally published at https://www.drugpatentwatch.com/blog/accelerating-drug-approvals-us/ By: Pankaj Mondal, DrugPatentWatch Staff Writer When it comes to measuring the success of a new drug, the amount of time required to complete the entire approval process become a… The post Accelerating Drug Approvals in the US appeared first on DrugPatentWatch. The post Accelerating Drug Approvals in […]
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017. “Checkpoint inhibitors are a standard of care immunotherapy for metastatic melanoma,” said lead author Dr Sapna Patel, Assistant Professor, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, […]
In continuation of my update on Abatacept (Orencia) Results from a phase 2 clinical trial, presented by Seattle Children’s Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants. Abatacept, when added to […]
Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018. tazarotene If […]